Dark adaptation function, the recovery of vision when going from daylight to darkness, is the only biomarker of age-related macular degeneration (AMD). AdaptDx provides a practical and objective way to measure dark adaptation with a test that can be completed in just a few minutes.
Early detection and monitoring can prevent unnecessary vision loss by facilitating interventions at the earliest possible stages. Treatment with vitamin therapy (PreserVision AREDS 2 or MacuHealth) has proven as effective in managing dry AMD as anti-VEGF injection therapy in slowing the progression of AMD.
In clinical studies involving more than 1,000 patients, AdaptDx has proven to be 90% sensitive and 90% specific for the presence of AMD. The clinical studies were conducted at renowned research centers such as Harvard University, Duke University, the National Eye Institute, and the University of Alabama at Birmingham.